Faculty Opinions recommendation of Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.

2012 ◽  
Author(s):  
Nancy Lin ◽  
Ines Vaz-Luis
Keyword(s):  
Breast Cancer ◽  
Intravenous Administration ◽  
Clinical Stage ◽  
Randomised Trial ◽  
Stage I ◽  
Her2 Positive ◽  
Open Label ◽  
Phase 3 ◽  
Adjuvant Trastuzumab

scholarly journals 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

The Lancet ◽  
2019 ◽  
Vol 393 (10191) ◽  
pp. 2591-2598 ◽  
Author(s):  
Xavier Pivot ◽  
Gilles Romieu ◽  
Marc Debled ◽  
Jean-Yves Pierga ◽  
Pierre Kerbrat ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Randomised Trial ◽  
Final Analysis ◽  
Open Label ◽  
Phase 3 ◽  
Adjuvant Trastuzumab ◽  
Open Label Phase

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

2014 ◽  
Vol 15 (7) ◽  
pp. 689-699 ◽  
Author(s):  
Ian E Krop ◽  
Sung-Bae Kim ◽  
Antonio González-Martín ◽  
Patricia M LoRusso ◽  
Jean-Marc Ferrero ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
Versus Treatment

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

2013 ◽  
Vol 14 (8) ◽  
pp. 741-748 ◽  
Author(s):  
Xavier Pivot ◽  
Gilles Romieu ◽  
Marc Debled ◽  
Jean-Yves Pierga ◽  
Pierre Kerbrat ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Her2 Positive ◽  
Phase 3 ◽  
Adjuvant Trastuzumab
Sign in / Sign up

Export Citation Format

Share Document